Metformin provides superior neuroprotective potential compared to semaglutide in preventing diabetes-associated Alzheimer’s disease via dual actions
Abstract Background Alzheimer’s disease (AD) and Diabetes Mellitus Type II (DM2) share overlapping biological mechanisms, and diabetes increases the risk of developing AD. Treatments that modify the course of diabetes, such as metformin and semaglutide, have been proposed to protect the brain, but t...
Wedi'i Gadw mewn:
| Prif Awduron: | , , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Nature Portfolio
2026-02-01
|
| Cyfres: | Communications Medicine |
| Mynediad Ar-lein: | https://doi.org/10.1038/s43856-026-01471-3 |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|